Standard BioTools Inc. LAB NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score

51/100

3/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Standard BioTools Inc. (LAB) generated $-74.35M in operating cash flow for fiscal year 2025. After capital expenditures of $8.3M, free cash flow was $-82.65M.

Free cash flow margin was -96.9% of revenue. Cash conversion ratio was 0.99x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (43/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 0.99x suggests some earnings are non-cash items

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

51/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

73/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

43/100

Proven by this page

✓

GROWTH

65/100

→ Income

✗

INCOME

10/100

→ Income

Standard BioTools Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-74.35M	$-74.35M	$-143.45M	$-43.29M	$-89.37M
Capital Expenditure	$-8.3M	$-8.3M	$-8.36M	$-2.83M	$-3.83M
Free Cash Flow	$-82.65M	$-82.65M	$-151.81M	$-46.12M	$-93.2M